P-222: A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients
Titel:
P-222: A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients
Auteur:
Silvennoinen, Raija Waage, Anders Peceliunas, Valdas Schjesvold, Fredrik Anttila, Pekka Uttervall, Katarina Säily, Marjaana Putkonen, Mervi Carlson, Kristina Haukas, Einar Sankelo, Marja Partanen, Anu Szatkowski, Damian Hansson, Markus Marttila, Anu Svensson, Ronald Axelsson, Per Lauri, Birgitta Mikkola, Maija Karlsson, Conny Abelsson, Johanna Ahlstrand, Erik Sikiö, Anu Nahi, Hareth